Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer

摘要: High insulin-like growth factor-I (IGF-I) levels are associated with an increased risk of breast cancer in premenopausal women. Because the synthetic retinoid fenretinide showed a beneficial effect on second cancers women Phase III trial, we studied its long-term effects IGF-I levels. We measured, at yearly intervals for up to 5 years, circulating IGF-I, IGF binding protein (BP)-3, and their molar ratio 60 subjects ≤50 years age >50 allocated either or no treatment. In age, measurements IGF-II, IGFBP-1, IGFBP-2 were also performed. The associations between biomarkers drug metabolite plasma concentrations investigated. All relatively stable over control group. Compared controls after adjustment baseline, treatment 1 year induced following changes: −13% [95% confidence interval (CI), −25 1%] −3% (95% CI, −16 13%) age; IGFBP-3, −4% −12 6%) both groups; IGF-I:IGFBP-3 ratio, −11% −22 1%) 1% −11 16%) age. These apparently maintained although fewer samples available as time progressed. No change other components was observed. Drug negatively correlated Fenretinide induces moderate decline association reduction warrants further study.